US FDA approves Gore Viabahn expandable stent graft for iliac artery use

Gore Viabahn VBX

The Gore Viabahn VBX balloon expandable endoprosthesis has received US Food & Drug Administration (FDA) approval for treatment of de novo or restenotic lesions found in iliac arteries, including lesions at the aortic bifurcation. This marks the availability of the only balloon expandable stent graft with an indication for the iliac artery.

“The VBX stent graft demonstrated notable immediate and nine-month safety and efficacy in treating patients with iliac occlusive disease which can be attributed to the exceptional device design,” says Jean Bismuth, vascular surgeon at /Houston Methodist, Houston, USA. “Overall, there were multiple clinical benefits observed, including no median change in the device length upon deployment and a 100% technical success rate with no occurrences of stent dislodgement or significant residual stenosis. The study device performed well in disadvantaged lesions, including occlusions, which speaks to its trackability, radial strength, conformability, and stent retention.”

Of the patients in the Gore VBX FLEX IDE clinical study (n=134), 32% presented with TASC II type C or D lesions, 18% required contralateral access to the lesion, and 42% involved kissing stents at the aortic bifurcation. Clinical data from the Gore VBX FLEX IDE clinical study conducted for FDA approval reflected that the design components of the VBX stent graft were resilient both during stenting procedures and over time:

  • 100% success rate in device delivery and coverage of target lesions in all study subjects;
  • 100%success rate in reducing the target lesion to less than or equal to 30 percent of the original stenosis;
  • No change in median length of the device upon deployment; and
  • 96.9% primary patency at nine-months, including a 95.3% primary patency rate in those patients with TASC II C or D type lesions.

Further, there were no reported incidences of device dislodgement, failures in stent integrity, or device-related serious adverse events through the primary endpoint follow up, meaning no additional costs incurred for either endovascular or surgical stent removal. The VBX stent graft does not require pre-dilation, which is intended to reduce the number of balloons required, and the longer lengths available reduce the need to use multiple stents for extensive lesions, both of which also contribute to procedural cost savings.